Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • ERS Author FAQs
    • COVID-19 submission information
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • ERS Author FAQs
    • COVID-19 submission information
  • Alerts
  • Subscriptions

Avatar acceptability: Views from the Australian Cystic Fibrosis community on the use of personalised organoid technology to guide treatment decisions

L.K. Fawcett, C.E. Wakefield, S. Sivam, P.G. Middleton, P. Wark, J. Widger, A. Jaffe, S.A. Waters
ERJ Open Research 2020; DOI: 10.1183/23120541.00448-2020
L.K. Fawcett
1School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia
2Molecular and Integrative Cystic Fibrosis (miCF) Research Centre, University of New South Wales, Sydney and Sydney Children's Hospital, Sydney, NSW, Australia
3Department of Respiratory Medicine, Sydney Children's Hospital, Sydney, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for L.K. Fawcett
C.E. Wakefield
1School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia
4Kids Cancer Centre, Sydney Children's Hospital, Randwick, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Sivam
5Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P.G. Middleton
6Cystic Fibrosis Unit, Department of Respiratory & Sleep Medicine, Westmead Hospital, Sydney, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for P.G. Middleton
P. Wark
7Centre for Healthy Lungs, University of Newcastle, Newcastle, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Widger
1School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia
2Molecular and Integrative Cystic Fibrosis (miCF) Research Centre, University of New South Wales, Sydney and Sydney Children's Hospital, Sydney, NSW, Australia
3Department of Respiratory Medicine, Sydney Children's Hospital, Sydney, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Jaffe
1School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia
2Molecular and Integrative Cystic Fibrosis (miCF) Research Centre, University of New South Wales, Sydney and Sydney Children's Hospital, Sydney, NSW, Australia
3Department of Respiratory Medicine, Sydney Children's Hospital, Sydney, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S.A. Waters
1School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia
2Molecular and Integrative Cystic Fibrosis (miCF) Research Centre, University of New South Wales, Sydney and Sydney Children's Hospital, Sydney, NSW, Australia
3Department of Respiratory Medicine, Sydney Children's Hospital, Sydney, NSW, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for S.A. Waters
  • For correspondence: Shafagh.waters@unsw.edu.au
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background Patient-oriented research approaches that reflect the needs and priorities of those most affected by health research outcomes, improves translation of research findings into practice. Development of targeted therapies for Cystic Fibrosis (CF) is a viable treatment option now for some eligible individuals despite the heterogeneous patient-specific therapeutic response. This has necessitated development of a clinical tool that predicts treatment response for individual patients. Patient-derived mini-organs (organoids) have been at the forefront of this development. However, little is known about their acceptability in CF patients and members of the public.

Methods We used a cross-sectional observational design to conduct an online survey in people with CF, their carers and community comparisons. Acceptability was examined in five domains; 1-willingness to use organoids, 2-perceived advantages and disadvantages of organoids, acceptable 3-out-of-pocket costs, 4-turnaround time, and 5-source of tissue.

Results 188 participants completed the questionnaire, including adults with CF and parents of children with CF (90(48%)), and adults without CF and parents of children without CF (98(52%)). Use of organoids to guide treatment decisions in CF was acceptable to 86(95%) CF participants and 98 (100%) community participants. The most important advantage was that organoids may improve treatment selection, improving the patient's quality of life and life expectancy. The most important disadvantage was that the organoid recommended treatment may be unavailable or too expensive.

Conclusions These findings indicate acceptance of patient-derived organoids as a tool to predict treatment response by the majority of people surveyed. This may indicate successful future implementation into healthcare systems.

Footnotes

This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.

Conflict of interest: Dr. Fawcett has nothing to disclose.

Conflict of interest: Prof. Wakefield has nothing to disclose.

Conflict of interest: Dr. SIvam has nothing to disclose.

Conflict of interest: Prof. Middleton has nothing to disclose.

Conflict of interest: Prof. Wark has nothing to disclose.

Conflict of interest: Dr. Widger has nothing to disclose.

Conflict of interest: Prof. Jaffe has nothing to disclose.

Conflict of interest: Dr. Waters has nothing to disclose.

This is a PDF-only article. Please click on the PDF link above to read it.

  • Received June 30, 2020.
  • Accepted September 18, 2020.
  • Copyright ©ERS 2020
http://creativecommons.org/licenses/by-nc/4.0/

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

PreviousNext
Back to top
Vol 7 Issue 1 Table of Contents
ERJ Open Research: 7 (1)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Avatar acceptability: Views from the Australian Cystic Fibrosis community on the use of personalised organoid technology to guide treatment decisions
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Avatar acceptability: Views from the Australian Cystic Fibrosis community on the use of personalised organoid technology to guide treatment decisions
L.K. Fawcett, C.E. Wakefield, S. Sivam, P.G. Middleton, P. Wark, J. Widger, A. Jaffe, S.A. Waters
ERJ Open Research Jan 2020, 00448-2020; DOI: 10.1183/23120541.00448-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Avatar acceptability: Views from the Australian Cystic Fibrosis community on the use of personalised organoid technology to guide treatment decisions
L.K. Fawcett, C.E. Wakefield, S. Sivam, P.G. Middleton, P. Wark, J. Widger, A. Jaffe, S.A. Waters
ERJ Open Research Jan 2020, 00448-2020; DOI: 10.1183/23120541.00448-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
  • Info & Metrics
  • PDF

Subjects

  • CF and non-CF bronchiectasis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Microbial and clinical factors are related to recurrence of symptoms after childhood lower respiratory tract infection
  • Pulmonary Hypertension in Eosinophilic Versus Non-Eosinophilic COPD
  • Nasal upregulation of CST1 in dog sensitised children with severe allergic airway disease
Show more Original article

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2021 by the European Respiratory Society